aTYR PHARMA INC — Director's Dealing 2022

Jan 18, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2022-01-13

Reporting Person: Broadfoot Jill Marie (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-13	Common stock	P	1923	$6.75	Acquired	12112	Direct

Footnotes

F1: Includes 178 shares acquired under the Company's 2015 Employee Stock Purchase Plan on November 15, 2021.